Last $7.91 USD
Change Today +0.01 / 0.13%
Volume 1.5M
SPPI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

spectrum pharmaceuticals inc (SPPI) Snapshot

Open
$7.90
Previous Close
$7.90
Day High
$7.97
Day Low
$7.75
52 Week High
01/23/14 - $10.32
52 Week Low
04/15/14 - $6.36
Market Cap
518.8M
Average Volume 10 Days
1.8M
EPS TTM
$-1.26
Shares Outstanding
65.6M
EX-Date
12/18/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRUM PHARMACEUTICALS INC (SPPI)

spectrum pharmaceuticals inc (SPPI) Related Bloomberg News

View More Bloomberg News

spectrum pharmaceuticals inc (SPPI) Related Businessweek News

No Related Businessweek News Found

spectrum pharmaceuticals inc (SPPI) Details

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

226 Employees
Last Reported Date: 03/12/14
Founded in 1987

spectrum pharmaceuticals inc (SPPI) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.8M
President and Chief Operating Officer
Total Annual Compensation: $710.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $462.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $586.3K
Compensation as of Fiscal Year 2013.

spectrum pharmaceuticals inc (SPPI) Key Developments

Spectrum Pharmaceuticals, Inc. Receives FDA Approval for New Drug Application of Beleodaq

Spectrum Pharmaceuticals, Inc. received notification from the U.S. Food and Drug Administration of their early action granting accelerated approval of the company's New Drug Application for Beleodaq (belinostat) for Injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication was approved by FDA under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).

Spectrum Pharmaceuticals, Inc. Appoints Deloitte & Touche LLP as the Independent Registered Public Accounting Firm for the Year Ending December 31, 2014

Spectrum Pharmaceuticals, Inc. announced that its annual meeting of stockholders held on June 27, 2014 approved the appointment of Deloitte & Touche LLP as the independent registered public accounting firm to audit the company’s financial statements for the year ending December 31, 2014.

Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012

Spectrum Pharmaceuticals announced that the key phase 2 trial of its long-acting granulocyte stimulating factor analog developed using LAPSCOVERY technology (SPI-2012) has completed its Phase 2 study enrollment; this positions Spectrum for Phase 3 decision making before year end. Spectrum's Phase 2 trial is a multicenter, dose-ranging study that evaluates the effectiveness and safety of SPI-2012 relative to a fixed, standard dose of pegfilgrastim as a concurrent active control. The primary objective and endpoint of this study is to assess the effect of SPI-2012 on the mean duration of severe neutropenia during Cycle 1 in patients with breast cancer who are candidates for adjuvant or neoadjuvant chemotherapy. Three doses of SPI-2012 were evaluated compared to pegfilgrastim. In January 2012, Spectrum entered into a co-development and commercialization agreement with Hanmi, gaining global rights for SPI-2012 except Korea, China, and Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPI:US $7.91 USD +0.01

SPPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.07 USD +0.01
GlaxoSmithKline SAE £12.80 EGP 0.00
Insys Therapeutics Inc $25.30 USD -0.88
Pfizer Ltd/India 1,358 INR -6.10
Wyeth Ltd 925.90 INR +4.35
View Industry Companies
 

Industry Analysis

SPPI

Industry Average

Valuation SPPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRUM PHARMACEUTICALS INC, please visit www.sppirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.